Lantern Pharma (LTRN) Expected to Announce Earnings on Wednesday

Lantern Pharma (NASDAQ:LTRN) is projected to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to post earnings of ($0.35) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 9:00 AM ET.

Lantern Pharma (NASDAQ:LTRN) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.19).

Lantern Pharma Price Performance

NASDAQ LTRN opened at $0.62 on Wednesday. The company has a market cap of $9.20 million, a P/E ratio of -0.39 and a beta of 2.48. Lantern Pharma has a 1-year low of $0.58 and a 1-year high of $4.34. The stock has a 50-day moving average of $1.23 and a two-hundred day moving average of $2.45.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Lantern Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lantern Pharma in a report on Tuesday, October 27th. One analyst has rated the stock with a Sell rating. According to MarketBeat, Lantern Pharma presently has an average rating of “Sell”.

Lantern Pharma Company Profile

Lantern Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing precision cancer therapies. The company combines artificial intelligence, machine learning and genomic analysis to identify drug candidates, patient populations and biomarkers that may support more targeted oncology treatments.

Lantern Pharma’s technology platform, RADR, is designed to analyze large volumes of biological, genomic and clinical data to help accelerate drug discovery and development. The platform is used to evaluate existing and novel therapeutic compounds, identify potential mechanisms of action and support the development of biomarker-driven clinical programs.

The company’s oncology pipeline has included investigational therapies for solid tumors and hematologic cancers, including programs such as LP-184 and LP-284.